Platinum
- Generic Name
- Platinum
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Pt
- CAS Number
- 7440-06-4
- Unique Ingredient Identifier
- 49DFR088MY
- Background
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallop...
- Associated Conditions
- -
- Associated Therapies
- -
Trial of BMS-986012 in Combination With Platinum and Etoposide
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT02815592
- Locations
- 🇪🇸
Local Institution - 0002, Barcelona, Spain
🇪🇸Local Institution - 0004, Madrid, Spain
🇪🇸Local Institution - 0010, Malaga, Spain
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Xinjiang Medical University
- Target Recruit Count
- 120
- Registration Number
- NCT02489409
- Locations
- 🇨🇳
Third Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China
An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Oncozyme Pharma Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT01844791
- Locations
- 🇵🇱
Ewa Kalinka-Warzocha, Lodz, Poland
Randomized Gefitinib Trial
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Fondazione Humanitas per la Ricerca
- Target Recruit Count
- 1
- Registration Number
- NCT00807066
- Locations
- 🇮🇹
Fondazione Humanitas per la Ricerca, Rozzano, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.